Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer
Launched by UNIVERSITY COLLEGE, LONDON · May 28, 2015
Trial Information
Current as of May 22, 2025
Unknown status
Keywords
ClinConnect Summary
Many cancer patients have sexual difficulties , gynaecologic cancer (Gyn-Onc) patients are particularly vulnerable to changes in sexual activity and lack of sexual desire with sexual difficulty rates estimated between 40 and 100% . Women undergo a range of treatments for ovarian, cervix, womb and vulval cancer with different combinations of surgery, chemotherapy, and radiation. Some treatments have a deleterious effect on women's internal and external sex organs, surrounding tissues and nerves, and render some menopausal. Following such treatments women report a wide range of difficulties i...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women over 18 (with partners at their choice) treated for any gynaecological malignancy with surgery and/or chemotherapy and/or radiation at UCLH (University College London Hospitals) Gynaecological Cancer Centre or University Hospitals Bristol Gynaecological Cancer Centre
- • 3 months minimum post end of treatment
- • any sexual orientation
- • with sexual function difficulties identified by initial screen (3 clinical questions within clinical interview posed by doctor or nurse)
- Exclusion Criteria:
- • Poor English
- • Current drug or alcohol abuse
- • Current sexual therapy or psychotherapy
About University College, London
University College London (UCL) is a leading global research institution renowned for its commitment to advancing healthcare through innovative clinical trials. As a prominent sponsor of clinical research, UCL leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous investigations aimed at improving patient outcomes and addressing pressing medical challenges. The institution fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring that its trials adhere to the highest ethical standards and regulatory guidelines. UCL's dedication to translating scientific discoveries into practical applications underscores its role as a vital contributor to the advancement of medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Susan F Gessler, PhD
Principal Investigator
University College, London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials